Application of aromatase inhibitors in endocrine responsive breast cancers

Breast

Volumn 16, Issue 2 SUPPL., 2007, Pages 114-119

  Goss, Paul ^a   Wu, Melinda ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adjuvant therapy; Aromatase inhibitors; Endocrine therapy resistance; Extended treatment

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ATAMESTANE; BEVACIZUMAB; CP 751871; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GOSERELIN; LAPATINIB; LETROZOLE; MONOCLONAL ANTIBODY; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TOREMIFENE; TRASTUZUMAB; TRIPTORELIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; GENE OVEREXPRESSION; HEART DISEASE; HEART FAILURE; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; MONOTHERAPY; MYALGIA; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR BINDING; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TIME SERIES ANALYSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VAGINAL DRYNESS;

EID: 35648952653     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.07.011     Document Type: Article

References (31)

1. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 3 (2005) 619-629
2. Buzdar A., Howell A., Cuzick J., et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7 8 (2006) 633-643
3. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New Engl J Med 349 19 (2003) 1793-1802
4. Whelan T.J., and Pritchard K.I. Managing patients on endocrine therapy: focus on quality-of-life issues. Clin Cancer Res 12 3 Pt 2 (2006) 1056s-1060s
5. Fallowfield L., Cella D., Cuzick J., Francis S., Locker G., and Howell A. Quality of life of postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 22 21 (2004) 4261-4271
6. Fallowfield L.J., Bliss J.M., Porter L.S., et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24 6 (2006) 910-917
7. Whelan T.J., Goss P.E., Ingle J.N., et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23 28 (2005) 6931-6940
8. Love R.R., Mazess R.B., Barden H.S., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. New Engl J Med 326 13 (1992) 852-856
9. Powles T.J., Hickish T., Kanis J.A., Tidy A., and Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14 1 (1996) 78-84
10. Chien A.J., and Goss P.E. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 24 33 (2006) 5305-5312
11. Goss P.E., Chlebowski R.T., LeBoff M.S., Cosman F., Singer F.R., and Sledge G.W. Recommendations on bone health management for women with early stage breast cancer. Am J Oncol Rev 5 3 (2005) 34-43
12. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 5 (2007) 486-492
13. Goss P.E., Qi S., Cheung A.M., Hu H., Mendes M., and Pritzker K.P. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res 10 17 (2004) 5717-5723
14. Goss P.E., Qi S., Josse R.G., et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 34 3 (2004) 384-392
15. Geisler J., Haynes B., Anker G., Dowsett M., and Lonning P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20 3 (2002) 751-757
16. Geisler J., King N., Anker G., et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4 9 (1998) 2089-2093
17. Geisler J., King N., Dowsett M., et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74 8 (1996) 1286-1291
18. Cui X., Schiff R., Arpino G., Osborne C.K., and Lee A.V. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23 30 (2005) 7721-7735
19. Osborne C.K., Bardou V., Hopp T.A., et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95 5 (2003) 353-361
20. Shou J., Massarweh S., Osborne C.K., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96 12 (2004) 926-935
21. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 18 (2001) 3808-3816
22. Zhu L., Chow L.W., Loo W.T., Guan X.Y., and Toi M. Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. Clin Cancer Res 10 14 (2004) 4639-4644
23. Goss P.E., Bondarenko I.N., Manikhas G.N., Pendergrass K.B., Miller W.H., and for the 777 CLP-29 Study Group. Phase 3 study of atamestane+toremifene vs. letrozole in advanced breast cancer. J Clin Oncol 2006 ASCO Annu Meet Proc 24 18s (2006) LBA525
24. Perez-Tenorio G., Stal O., and Southeast Sweden Breast Cancer Group. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Brit J Cancer 12:86 4 (2002) 540-545
25. Kurokawa H., Lenferink A.E., Simpson J.F., et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60 20 (2000) 5887-5894
26. Kurokawa H., and Arteaga C.L. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 9 1 Pt 2 (2003) 511S-515S
27. deGraffenried L.A., Hilsenbeck S.G., and Fuqua S.A. Sp1 is essential for estrogen receptor alpha gene transcription. J Steroid Biochem Mol Biol 82 1 (2002) 7-18
28. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 9453 (2005) 60-62
29. Boccardo F., Rubagotti A., Guglielmini P., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17 Suppl. 7 (2006) vii10-vvii4
30. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 9484 (2005) 455-462
31. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New Engl J Med 350 11 (2004) 1081-1092